Global Generic Injectables Market Growth (Status and Outlook) 2025-2031

Global Generic Injectables Market Growth (Status and Outlook) 2025-2031

The global Generic Injectables market size is predicted to grow from US$ 32060 million in 2025 to US$ 39710 million in 2031; it is expected to grow at a CAGR of 3.6% from 2025 to 2031.

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.

The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

LPI (LP Information)' newest research report, the “Generic Injectables Industry Forecast” looks at past sales and reviews total world Generic Injectables sales in 2024, providing a comprehensive analysis by region and market sector of projected Generic Injectables sales for 2025 through 2031. With Generic Injectables sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Generic Injectables industry.

This Insight Report provides a comprehensive analysis of the global Generic Injectables landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Generic Injectables portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Generic Injectables market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Injectables and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Injectables.

This report presents a comprehensive overview, market shares, and growth opportunities of Generic Injectables market by product type, application, key players and key regions and countries.

Segmentation by Type:
Small Molecule
Large Molecule

Segmentation by Application:
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC

Please note: The report will take approximately 2 business days to prepare and deliver.